Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription

Articles published in Br J Haematol

Retrieve available abstracts of 310 articles:
HTML format

Single Articles

    December 2022
  1. LI H, Xiang X, Ding H, Yu J, et al
    Differentiation therapy using low-dose venetoclax in a variant acute promyelocytic leukaemia carrying ZBTB16-RARA.
    Br J Haematol. 2022;199:768-771.

  2. CANALI A, Rieu JB
    Morphological characterization of acute myeloid leukaemia with t(11;17)(q23;q21)/ZBTB16::RARA fusion.
    Br J Haematol. 2022;199:638.

  3. WEI S, Gu R, Song Y, Yan Z, et al
    Early-salvage therapy with venetoclax-based regimens for induction failure and poor early response acute lymphoblastic leukaemia: A retrospective case series of 13 patients.
    Br J Haematol. 2022;199:772-776.

  4. ATKINS O, Mirvis E, Maynard S, Katsomitrou V, et al
    Acute myeloid leukaemia presenting with Sweet syndrome.
    Br J Haematol. 2022;199:637.

  5. MUNIR T, Emmerson J, Hockaday A, Oughton JB, et al
    Obinutuzumab as consolidation after chemo-immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial.
    Br J Haematol. 2022;199:707-719.
    PubMed     Abstract available

    Treatment of blast phase chronic myeloid leukaemia: A rare and challenging entity.
    Br J Haematol. 2022;199:665-678.
    PubMed     Abstract available

    November 2022
    ATM serine/threonine kinase germline mutations in chronic lymphocytic leukaemia come in different flavours.
    Br J Haematol. 2022;199:307-309.

  8. PETRACKOVA A, Savara J, Turcsanyi P, Gajdos P, et al
    Rare germline ATM variants of uncertain significance in chronic lymphocytic leukaemia and other cancers.
    Br J Haematol. 2022;199:371-381.
    PubMed     Abstract available

  9. LI T, Wu P, Wang A, Chen M, et al
    A rare case of transformation from relapsed acute monocytic leukaemia with KMT2A::MLLT10 to acute megakaryoblastic leukaemia.
    Br J Haematol. 2022;199:305.

  10. FORDHAM NJ, Bartram J, Ghorashian S, O'Connor D, et al
    What is the diagnostic yield of bone marrow aspiration to exclude leukaemia prior to systemic treatment in juvenile idiopathic arthritis?
    Br J Haematol. 2022;199:447-451.

    Asciminib for chronic myeloid leukaemia: Next questions.
    Br J Haematol. 2022;199:322-331.
    PubMed     Abstract available

  12. WAN Y, Zhang H, Zhang L, Cai J, et al
    Extended vincristine and dexamethasone pulse therapy may not be necessary for children with TCF3-PBX1 positive acute lymphoblastic leukaemia.
    Br J Haematol. 2022;199:587-596.
    PubMed     Abstract available

  13. WANG Y, Chen S, Chi P, Nie R, et al
    Survival prediction optimization of acute myeloid leukaemia based on T-cell function-related genes and plasma proteins.
    Br J Haematol. 2022;199:572-586.
    PubMed     Abstract available

  14. KRISTENSEN DT, Nielsen LB, Jakobsen LHK, Kristensen TC, et al
    Effects of chemotherapy dose reductions in overweight patients with acute myeloid leukaemia: A Danish nationwide cohort study.
    Br J Haematol. 2022;199:539-548.
    PubMed     Abstract available

  15. ZHAO C, Wang S, Wang K
    Mutual exclusivity between the fusion gene CBFB::MYH11 and somatic mitochondrial mutations in acute myeloid leukaemia.
    Br J Haematol. 2022;199:e25-e29.

  16. QIANG X, Chen S, Chen X
    Peritoneal infiltration by leukaemic promyelocytes in acute promyelocytic leukaemia at initial diagnosis.
    Br J Haematol. 2022;199:475.

  17. KOTMAYER L, Romero-Moya D, Marin-Bejar O, Kozyra E, et al
    GATA2 deficiency and MDS/AML: Experimental strategies for disease modelling and future therapeutic prospects.
    Br J Haematol. 2022;199:482-495.
    PubMed     Abstract available

    October 2022
  18. ANDERSSON NG, Rathe M, Molle I, Jarvis KB, et al
    A survey on thromboprophylaxis and coagulation assessment in children and young adults with acute lymphoblastic leukaemia (ALL) in the Nordic and Baltic countries: Different practices of assessment and management.
    Br J Haematol. 2022;199:117-121.
    PubMed     Abstract available

    Screening for mercaptopurine intolerance in ALL - target the genes or their product?
    Br J Haematol. 2022;199:173-174.
    PubMed     Abstract available

  20. DENNIS M, Copland M, Kaur H, Kell J, et al
    Management of older patients with frailty and acute myeloid leukaemia: A British Society for Haematology good practice paper.
    Br J Haematol. 2022;199:205-221.

  21. TANAKA Y, Urayama KY, Mori M, Arakawa Y, et al
    Prominence of NUDT15 genetic variation associated with 6-mercaptopurine tolerance in a genome-wide association study of Japanese children with acute lymphoblastic leukaemia.
    Br J Haematol. 2022;199:260-269.
    PubMed     Abstract available

  22. YOSHIDA M, Brown SA, Moriyama T, Nishii R, et al
    Low NUDT15 expression levels due to biallelic NUDT15 variants and 6-mercaptopurine intolerance.
    Br J Haematol. 2022;199:270-276.
    PubMed     Abstract available

  23. DILLON J, Mykytiv V, Keenan C, Mullaney B, et al
    Management of a patient with acute myeloid leukaemia with a diagnosis of type 2 von Willebrand disease and a novel variant within the von Willebrand factor (VWF) gene.
    Br J Haematol. 2022;199:e5-e7.

  24. ALSOUQI A, Rothenberger SD, Boyiadzis M, Lontos K, et al
    Time from diagnosis to treatment is associated with survival in patients with acute myeloid leukaemia: An analysis of 55 985 patients from the National Cancer Database.
    Br J Haematol. 2022;199:256-259.
    PubMed     Abstract available

  25. HAMPEL PJ, Rabe KG, Call TG, Ding W, et al
    Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia.
    Br J Haematol. 2022;199:239-244.
    PubMed     Abstract available

    September 2022
  26. GREINER J, Goetz M, Schuler PJ, Bulach C, et al
    Enhanced stimulation of antigen-specific immune responses against nucleophosmin 1 mutated acute myeloid leukaemia by an anti-programmed death 1 antibody.
    Br J Haematol. 2022;198:866-874.
    PubMed     Abstract available

  27. YEOH DK, Blyth CC, Kotecha RS
    Blinatumomab as bridging therapy in paediatric B-cell acute lymphoblastic leukaemia complicated by invasive fungal disease.
    Br J Haematol. 2022;198:887-892.
    PubMed     Abstract available

  28. ALBERTSEN BK, Lynggaard LS, Schmiegelow K
    Asparaginase encapsulated in erythrocytes as second-line treatment in hypersensitive patients with acute lymphoblastic leukaemia.
    Br J Haematol. 2022;198:e84-e85.

  29. BRECCIA M, Olimpieri PP, Celant S, Olimpieri O, et al
    Management of chronic myeloid leukaemia patients treated with ponatinib in a real-life setting: A retrospective analysis from the monitoring registries of the Italian Medicines Agency (AIFA).
    Br J Haematol. 2022;198:965-973.
    PubMed     Abstract available

  30. LI J, Liu L, Zhang R, Wan Y, et al
    Development and validation of a prognostic scoring model to risk stratify childhood acute myeloid leukaemia.
    Br J Haematol. 2022;198:1041-1050.
    PubMed     Abstract available

  31. VAN DER SLUIS IM, Bertrand Y, Baruchel A, Pieters R, et al
    Is asparaginase encapsulated in erythrocytes effective as second-line treatment in acute lymphoblastic leukaemia?
    Br J Haematol. 2022;198:e82-e83.

  32. MOGENSEN N, Saaranen E, Olsson E, Klug Albertsen B, et al
    Quality of life in mothers and fathers of children treated for acute lymphoblastic leukaemia in Sweden, Finland and Denmark.
    Br J Haematol. 2022;198:1032-1040.
    PubMed     Abstract available

    Metabolomics: A biomarker to improve the assessment of central nervous system positive acute lymphoblastic leukaemia?
    Br J Haematol. 2022;198:939-940.

  34. TAYLOR GP, Cook LB
    A new paradigm for the management of ATL.
    Br J Haematol. 2022;198:941-942.

  35. FAVINI C, Talotta D, Almasri M, Andorno A, et al
    Clonally unrelated Richter syndrome are truly de novo diffuse large B-cell lymphomas with a mutational profile reminiscent of clonally related Richter syndrome.
    Br J Haematol. 2022;198:1016-1022.
    PubMed     Abstract available

  36. HARRINGTON P, Dillon R, Radia D, McLornan D, et al
    Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T-cell phenotype.
    Br J Haematol. 2022;198:1011-1015.
    PubMed     Abstract available

  37. SONG Z, Tang G, Zhuang C, Wang Y, et al
    Metabolomic profiling of cerebrospinal fluid reveals an early diagnostic model for central nervous system involvement in acute lymphoblastic leukaemia.
    Br J Haematol. 2022;198:994-1010.
    PubMed     Abstract available

    August 2022
  38. ISIDORI A, Loscocco F, Visani G, Paolasini S, et al
    Real-life efficacy and safety of idelalisib in 55 double-refractory follicular lymphoma patients.
    Br J Haematol. 2022 Aug 24. doi: 10.1111/bjh.18426.
    PubMed     Abstract available

  39. IMBERY JF, Heinzelbecker J, Jebsen JK, McGowan M, et al
    T-helper cell regulation of CD45 phosphatase activity by galectin-1 and CD43 governs chronic lymphocytic leukaemia proliferation.
    Br J Haematol. 2022;198:556-573.
    PubMed     Abstract available

  40. WANG X, Tang G, Hu Z, Fang H, et al
    Myeloid neoplasms with 8q24/MYC rearrangement are frequently associated with myelodysplasia, complex karyotype, TP53 alterations, and inferior survival.
    Br J Haematol. 2022;198:604-608.

  41. SANCHEZ-VIZCAINO F, Tamayo C, Ramos F, Lainez-Gonzalez D, et al
    Identification of seasonal variation in the diagnosis of acute myeloid leukaemia: a population-based study.
    Br J Haematol. 2022;198:545-555.
    PubMed     Abstract available

  42. LU L, Kok CH, Dang P, Branford S, et al
    Highly sensitive droplet digital polymerase chain reaction for BCR::ABL1 messenger RNA identifies patients with chronic myeloid leukaemia with a low probability of achieving treatment-free remission.
    Br J Haematol. 2022;198:600-603.

  43. PODVIN B, Guermouche H, Fournier E, Berthon C, et al
    Acute myeloid leukaemia with double minute chromosomes encompassing the 8q24 region.
    Br J Haematol. 2022;198:413.

  44. CHAN WY, Zhu C, Sanchez E, Gupta R, et al
    Antibody responses to SARS-CoV-2 vaccination in patients with acute myeloid leukaemia and high risk MDS on active anti-cancer therapies.
    Br J Haematol. 2022;198:478-481.

  45. HERAUDET L, Galtier J, Favre S, Peyraud F, et al
    VANDA regimen followed by blinatumomab leads to favourable outcome in patients with Philadelphia chromosome-negative B-precursor acute lymphoblastic leukaemia in first relapse.
    Br J Haematol. 2022;198:523-527.
    PubMed     Abstract available

  46. JAMY O, Lin K, Worth S, Bachiashvili K, et al
    Hypomethylating agent/venetoclax versus intensive chemotherapy in adults with relapsed or refractory acute myeloid leukaemia.
    Br J Haematol. 2022;198:e35-e37.

  47. ALHAJ ISSA Z, Altwijri A, Alfayez M
    Cerebral nocardiosis in ibrutinib-treated chronic lymphocytic leukaemia.
    Br J Haematol. 2022;198:414.

  48. ADES L, Duployez N, Guerci-Bresler A, Laribi K, et al
    A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations.
    Br J Haematol. 2022;198:535-544.
    PubMed     Abstract available

  49. RUSSELL NH, Hills RK, Kjeldsen L, Clark RE, et al
    A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial.
    Br J Haematol. 2022;198:528-534.
    PubMed     Abstract available

  50. VALTIS YK, Place AE, Silverman LB, Vrooman LM, et al
    Orthopaedic adverse events among adolescents and adults treated with asparaginase for acute lymphoblastic leukaemia.
    Br J Haematol. 2022;198:421-430.
    PubMed     Abstract available

  51. VOLPE VO, Al Ali N, Chan O, Padron E, et al
    Splicing factor 3B subunit 1 (SF3B1) mutation in the context of therapy-related myelodysplastic syndromes.
    Br J Haematol. 2022;198:713-720.
    PubMed     Abstract available

  52. MULLIGAN SP, Opat S, Marlton P, Kuss B, et al
    Ibrutinib use, treatment duration, and concomitant medications in Australian patients with relapsed or refractory chronic lymphocytic leukaemia.
    Br J Haematol. 2022;198:790-793.

  53. GENTHON A, Dragoi D, Memoli M, Hirsch P, et al
    Isocitrate dehydrogenase inhibitors as a bridge to allogeneic stem cell transplant in relapsed or refractory acute myeloid leukaemia.
    Br J Haematol. 2022;198:780-784.

  54. LAURA CS, Ana FM, Ines LH
    Pure erythroid leukaemia mimicking metastatic carcinoma.
    Br J Haematol. 2022;198:617.

    July 2022
  55. STRATI P, Coleman M, Champion R, Ma S, et al
    A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma.
    Br J Haematol. 2022 Jul 21. doi: 10.1111/bjh.18368.
    PubMed     Abstract available

  56. ROLDAN GALIACHO V, Zaldumbide Duenas L, Lobo Olmedo A, Alonso Varela M, et al
    Intracytoplasmic crystalline inclusions in peripheral blood lymphocytes in small lymphocytic lymphoma.
    Br J Haematol. 2022 Jul 21. doi: 10.1111/bjh.18380.

  57. MEYER LK, Delgado-Martin C, Sharp PP, Huang BJ, et al
    Inhibition of the Sec61 translocon overcomes cytokine-induced glucocorticoid resistance in T-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2022;198:137-141.
    PubMed     Abstract available

  58. GHANDILI S, Kluger MA, Leitner T, Grahammer F, et al
    Donor-transmitted extramedullary acute myeloid leukaemia after living donor kidney transplantation.
    Br J Haematol. 2022;198:199-202.

  59. KRIEL M, Opie J, Louw V, Musekwa E, et al
    Clover leaf nuclear morphology in chronic lymphocytic leukaemia with typical immunophenotype and absence of trisomy 12.
    Br J Haematol. 2022;198:8.

  60. PIMENTEL-VILLAR MA, Morales-Camacho RM, Vargas MT, Jimenez-Jambrina M, et al
    Erythrophagocytosis by blast cells in B-lymphoblastic leukaemia with BCR-ABL1.
    Br J Haematol. 2022;198:7.

    Beware clonal haematopoiesis following chronic lymphocytic leukaemia treatment.
    Br J Haematol. 2022;198:9-10.

  62. SIDHU J, Masurekar AN, Gogoi MP, Fong C, et al
    Activity and toxicity of intramuscular 1000 iu/m(2) polyethylene glycol-E. coli L-asparaginase in the UKALL 2003 and UKALL 2011 clinical trials.
    Br J Haematol. 2022;198:142-150.
    PubMed     Abstract available

  63. WANG J, Jiang H, Jing Y, Su L, et al
    Prognostic implications of the detection of measurable residual disease and mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA.
    Br J Haematol. 2022;198:e3-e8.

  64. VOSO MT, Pandzic T, Falconi G, Dencic-Fekete M, et al
    Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy.
    Br J Haematol. 2022;198:103-113.
    PubMed     Abstract available

  65. DE PROPRIS MS, Musiu P, Intoppa S, Nardacci MG, et al
    Hairy cell leukaemia with low CD103 expression: A rare but important diagnostic pitfall.
    Br J Haematol. 2022;198:e28-e31.

  66. STENGEL S, Petrie KR, Sbirkov Y, Stanko C, et al
    Suppression of MYC by PI3K/AKT/mTOR pathway inhibition in combination with all-trans retinoic acid treatment for therapeutic gain in acute myeloid leukaemia.
    Br J Haematol. 2022;198:338-348.
    PubMed     Abstract available

  67. DHUNPUTH C, Strullu M, Petit A, Merched M, et al
    Single-dose (4.5 mg/m(2) ) gemtuzumab ozogamicin in combination with fludarabine, cytarabine and anthracycline as reinduction therapy in relapsed or refractory paediatric acute myeloid leukaemia.
    Br J Haematol. 2022;198:373-381.
    PubMed     Abstract available

  68. SHIVAROV V, Grigorova D
    Dynamic trends in life expectancy and life years lost over five decades in patients from the SEER database with chronic myeloid leukaemia.
    Br J Haematol. 2022;198:e23-e25.

  69. GUO JJ, Cao L, Zhu HY, Miao Y, et al
    T-cell large granular lymphocytic leukaemia with atypical immunophenotypes: A single-centre retrospective analysis of 17 cases.
    Br J Haematol. 2022;198:e18-e22.

    June 2022
  70. KATAYAMA S, Hiraishi T, Ota M
    Skin manifestations of intravascular adult T-cell leukaemia/lymphoma.
    Br J Haematol. 2022 Jun 27. doi: 10.1111/bjh.18318.

  71. BRIVIO E, Cossio A, Borra D, Silvestri D, et al
    Osteonecrosis in paediatric acute lymphoblastic leukaemia: Incidence, risk factors, radiological patterns and evolution in a single-centre cohort.
    Br J Haematol. 2022;197:602-608.
    PubMed     Abstract available

  72. WALEWSKA R, Parry-Jones N, Eyre TA, Follows G, et al
    Guideline for the treatment of chronic lymphocytic leukaemia.
    Br J Haematol. 2022;197:544-557.

  73. MOIA R, Gaidano G
    Updated revision of the British Society of Haematology guidelines for chronic lymphocytic leukaemia.
    Br J Haematol. 2022;197:513-514.

  74. WANG QQ, Wang HF, Zhao JZ, Naranmandura H, et al
    Venetoclax for arsenic-resistant acute promyelocytic leukaemia.
    Br J Haematol. 2022;197:e58-e60.

  75. MERLI P
    Treating second-relapsed/refractory first-relapsed childhood acute myeloid leukaemia: Successful salvage rather than palliation?
    Br J Haematol. 2022;197:651-652.
    PubMed     Abstract available

  76. WANG M, Lin H, Chu X, Wang Z, et al
    Identification of a recurrent fusion NUP98-RARG in acute myeloid leukaemia resembling acute promyelocytic leukaemia.
    Br J Haematol. 2022;197:e73-e78.

  77. LYNGGAARD LS, Vaitkeviciene G, Langenskiold C, Lehmann AK, et al
    Asparaginase encapsulated in erythrocytes as second-line treatment in hypersensitive patients with acute lymphoblastic leukaemia.
    Br J Haematol. 2022;197:745-754.
    PubMed     Abstract available

  78. TARIQ H, Barnea Slonim L, Coty Fattal Z, Alikhan MB, et al
    Therapy-related myeloid neoplasms with normal karyotype show distinct genomic and clinical characteristics compared to their counterparts with abnormal karyotype.
    Br J Haematol. 2022;197:736-744.
    PubMed     Abstract available

  79. MORI A, Onozawa M, Tsukamoto S, Ishio T, et al
    Humoral response to mRNA-based COVID-19 vaccine in patients with myeloid malignancies.
    Br J Haematol. 2022;197:691-696.
    PubMed     Abstract available

  80. WHITE T, Kaspers G, Abrahamsson J, Arad-Cohen N, et al
    Clinical outcomes of second relapsed and refractory first relapsed paediatric AML: A retrospective study within the NOPHO-DB SHIP consortium.
    Br J Haematol. 2022;197:755-765.
    PubMed     Abstract available

    May 2022
  81. SHICHIJO T, Nosaka K, Tatetsu H, Higuchi Y, et al
    Beneficial impact of first-line mogamulizumab-containing chemotherapy in adult T-cell leukaemia-lymphoma.
    Br J Haematol. 2022 May 24. doi: 10.1111/bjh.18281.
    PubMed     Abstract available

  82. ZHU K, Jamroz A, Huang S, Villa D, et al
    Outcomes of Hodgkin variant Richter transformation in chronic lymphocytic leukaemia and small lymphocytic lymphoma in British Columbia.
    Br J Haematol. 2022 May 14. doi: 10.1111/bjh.18241.
    PubMed     Abstract available

  83. JOBSON D, McCormack CJ, Mar V, Tam C, et al
    Impact of chronic lymphocytic leukaemia on melanoma outcomes: A retrospective case-control study.
    Br J Haematol. 2022;197:320-325.
    PubMed     Abstract available

  84. TAYLOR T, Byrne J, Errico G, Clark D, et al
    Very late extramedullary relapse of acute myeloid leukaemia as prostatic myeloid sarcoma occurring 24 years post-allograft.
    Br J Haematol. 2022;197:243.

  85. OLIVEIRA AF, Tansini A, Toledo T, Balceiro R, et al

    Br J Haematol. 2022;197:339-348.
    PubMed     Abstract available

  86. UJJANI C, Shadman M, Lynch RC, Tu B, et al
    The impact of B-cell-directed therapy on SARS-CoV-2 vaccine efficacy in chronic lymphocytic leukaemia.
    Br J Haematol. 2022;197:306-309.
    PubMed     Abstract available

  87. CARTWRIGHT A, Scott S, Francis S, Whitby L, et al
    Assessing the impact of the 2017 European LeukemiaNet recommendations on FLT3 allelic ratio calculation and reporting in acute myeloid leukaemia.
    Br J Haematol. 2022;197:e35-e37.

  88. PETERSEN MA, Rosenberg CA, Brondum RF, Aggerholm A, et al
    Immunophenotypically defined stem cell subsets in paediatric AML are highly heterogeneous and demonstrate differences in BCL-2 expression by cytogenetic subgroups.
    Br J Haematol. 2022;197:452-466.
    PubMed     Abstract available

  89. WEI H, Zhou C, Liu B, Lin D, et al
    The prognostic factors in acute myeloid leukaemia with double-mutated CCAAT/enhancer-binding protein alpha (CEBPAdm).
    Br J Haematol. 2022;197:442-451.
    PubMed     Abstract available

  90. LEW TE, Anderson MA
    Health-related quality of life for patients with chronic lymphocytic leukaemia - A critical outcome measure in the era of highly effective therapies.
    Br J Haematol. 2022;197:394-396.

  91. OERLEMANS S, Efficace F, Kieffer JM, Kyriakou C, et al
    International validation of the EORTC QLQ-CLL17 questionnaire for assessment of health-related quality of life for patients with chronic lymphocytic leukaemia.
    Br J Haematol. 2022;197:431-441.
    PubMed     Abstract available

  92. JACOBY E, Bielorai B, Hutt D, Itzhaki O, et al
    Parameters of long-term response with CD28-based CD19 chimaeric antigen receptor-modified T cells in children and young adults with B-acute lymphoblastic leukaemia.
    Br J Haematol. 2022;197:475-481.
    PubMed     Abstract available

  93. ALTER BP, Giri N, McReynolds LJ, Altintas B, et al
    Fanconi anaemia: A syndrome with distinct subgroups.
    Br J Haematol. 2022;197:467-474.
    PubMed     Abstract available

  94. YU Q, Yu D, Chen X
    Cup-shaped nuclei in acute promyelocytic leukaemia.
    Br J Haematol. 2022;197:389.

    April 2022
  95. SUN C
    COVID-19 vaccine response in chronic lymphocytic leukaemia is more than just seroconversion.
    Br J Haematol. 2022;197:11-12.

  96. SHEN Y, Freeman JA, Holland J, Solterbeck A, et al
    COVID-19 vaccine failure in chronic lymphocytic leukaemia and monoclonal B-lymphocytosis; humoural and cellular immunity.
    Br J Haematol. 2022;197:41-51.
    PubMed     Abstract available

  97. CLAUDIANI S, Apperley JF, Parker EL, Marchesin F, et al
    Durable humoral responses after the second anti-SARS-CoV-2 vaccine dose in chronic myeloid leukaemia patients on tyrosine kinase inhibitors.
    Br J Haematol. 2022;197:e1-e4.

  98. ON S, Rath CG, Lan M, Wu B, et al
    Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent.
    Br J Haematol. 2022;197:63-70.
    PubMed     Abstract available

  99. GADI D, Griffith A, Wang Z, Tyekucheva S, et al
    Idelalisib reduces regulatory T cells and activates T helper 17 cell differentiation in relapsed refractory patients with chronic lymphocytic leukaemia.
    Br J Haematol. 2022;197:207-211.
    PubMed     Abstract available

  100. RECKZEH K, Estruch M, Ali M, Sogaard Helbo A, et al
    TET2 deficiency cooperates with CBFB-MYH11 to induce acute myeloid leukaemia and represents an early leukaemogenic event.
    Br J Haematol. 2022;197:201-206.

    BCR::ABL1 transcripts and clinical outcome - interrogating the technique.
    Br J Haematol. 2022;197:9-10.

  102. DOMINY KM, Claudiani S, O'Hare M, Szydlo R, et al
    Assessment of quantitative polymerase chain reaction for BCR-ABL1 transcripts in chronic myeloid leukaemia: Are improved outcomes in patients with e14a2 transcripts an artefact of technology?
    Br J Haematol. 2022;197:52-62.
    PubMed     Abstract available

  103. VERBEEK MWC, Buracchi C, Laqua A, Nierkens S, et al
    Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies - a EuroFlow study.
    Br J Haematol. 2022;197:76-81.
    PubMed     Abstract available

  104. HILLS RK
    Historical controls and venous thromboembolism prophylaxis in acute lymphoblastic leukaemia: things can only get better?
    Br J Haematol. 2022;197:e26-e27.

  105. YEUNG DTO, Osborn MP, White DL
    B-cell acute lymphoblastic leukaemia: recent discoveries in molecular pathology, their prognostic significance, and a review of the current classification.
    Br J Haematol. 2022;197:13-27.
    PubMed     Abstract available

  106. TONG WH
    Does anticoagulation prophylaxis reduce the rate of venous thromboembolism in adult acute lymphoblastic leukaemia treated with asparaginase-based therapy?
    Br J Haematol. 2022;197:e24-e25.

  107. JENSEN K, Oskarsson T, Lahteenmaki P, Flaegstad T, et al
    Doing less, accomplishing more for childhood ALL: response.
    Br J Haematol. 2022;197:120.

    March 2022
  108. CULL G, Burger JA, Opat S, Gottlieb D, et al
    Zanubrutinib for treatment-naive and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study.
    Br J Haematol. 2022;196:1209-1218.
    PubMed     Abstract available

  109. MORIYA K, Imamura T, Katayama S, Kaino A, et al
    The incidence of symptomatic osteonecrosis is similar between Japanese children and children in Western countries with acute lymphoblastic leukaemia treated with a Berlin-Frankfurt-Munster (BFM)95-based protocol.
    Br J Haematol. 2022;196:1257-1261.
    PubMed     Abstract available

  110. MAAS CCHM, van Klaveren D, Ector GICG, Posthuma EFM, et al
    The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population-based study in the Netherlands, 1989-2018.
    Br J Haematol. 2022;196:1219-1224.
    PubMed     Abstract available

  111. BARZILAI-BIRENBOIM S, Elitzur S, Nirel R, Ehrenberg M, et al
    Elevated intraocular pressure in children with acute lymphoblastic leukaemia: A prospective study.
    Br J Haematol. 2022;196:1248-1256.
    PubMed     Abstract available

  112. DILLON R, Hills RK, Burnett AK, Russell NH, et al
    Gemtuzumab ozogamicin in (KMT2A)-rearranged adult acute myeloid leukaemia (AML) in the UK Medical Research Council AML15 and AML16 trials.
    Br J Haematol. 2022;196:e50-e52.

  113. WALDRON C, O'Brien D, Brophy S, Perera K, et al
    Epidemiology of chronic lymphocytic leukaemia in an Irish subpopulation with total case ascertainment: an additional tool for health economic planning.
    Br J Haematol. 2022;196:e47-e49.

  114. EGNELL C, Heyman M, Jonsson OG, Raja RA, et al
    Obesity as a predictor of treatment-related toxicity in children with acute lymphoblastic leukaemia.
    Br J Haematol. 2022;196:1239-1247.
    PubMed     Abstract available

  115. GALLIPOLI P, Clark RE, Byrne J, Apperley JF, et al
    The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukaemia.
    Br J Haematol. 2022;196:e55-e57.

  116. COATS T, Bean D, Basset A, Sirkis T, et al
    A novel algorithmic approach to generate consensus treatment guidelines in adult acute myeloid leukaemia.
    Br J Haematol. 2022;196:1337-1343.
    PubMed     Abstract available

  117. SALHOTRA A, Tsai NC, Zhang J, Ngo D, et al
    Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia.
    Br J Haematol. 2022;196:e71-e74.

  118. RUSSELL N, Hills R, Kjeldsen L, Dennis M, et al
    Treatment intensification with FLAG-Ida may improve disease control in younger patients with secondary acute myeloid leukaemia: long-term follow up of the MRC AML15 trial.
    Br J Haematol. 2022;196:1344-1347.
    PubMed     Abstract available

  119. MCCLURE BJ, Pal M, Heatley SL, Rehn J, et al
    Two novel cases of NUTM1-rearranged B-cell acute lymphoblastic leukaemia presenting with high-risk features.
    Br J Haematol. 2022;196:1407-1411.

  120. LINCH DC, Hills RK, Burnett AK, Russell N, et al
    Therapy for isocitrate dehydrogenase 2 (IDH2)(R172) -mutant acute myeloid leukaemia.
    Br J Haematol. 2022;196:1348-1352.
    PubMed     Abstract available

  121. BENDE RJ, Janssen J, van Noesel CJM
    Higher-order of chronic lymphocytic leukaemia (CLL) classification: shared antigenic specificities of stereotyped B-cell receptor subsets as defined by the European Research Initiative on CLL consortium.
    Br J Haematol. 2022;196:e60-e63.

  122. TAWANA K, Brown AL, Churpek JE
    Integrating germline variant assessment into routine clinical practice for myelodysplastic syndrome and acute myeloid leukaemia: current strategies and challenges.
    Br J Haematol. 2022;196:1293-1310.
    PubMed     Abstract available

    February 2022
    Is COVID-19 less severe in CML patients than in those with other haematological cancers?
    Br J Haematol. 2022;196:471-472.

  124. BRECCIA M, Abruzzese E, Accurso V, Attolico I, et al
    COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report.
    Br J Haematol. 2022;196:559-565.
    PubMed     Abstract available

  125. SCHENKER C, Hirzel C, Walti LN, Zeerleder SS, et al
    Convalescent plasma and remdesivir for protracted COVID-19 in a patient with chronic lymphocytic leukaemia: a case report of late relapse after rapid initial response.
    Br J Haematol. 2022;196:e27-e29.

  126. BIONDI A, Conter V, Chandy M, Ewald P, et al
    Precursor B-cell acute lymphoblastic leukaemia-a global view.
    Br J Haematol. 2022;196:530-547.
    PubMed     Abstract available

  127. SALEK C, Folber F, Fronkova E, Pecherkova P, et al
    Low levels of minimal residual disease after induction chemotherapy for BCR-ABL1-negative acute lymphoblastic leukaemia in adults are clinically relevant.
    Br J Haematol. 2022;196:706-710.
    PubMed     Abstract available

  128. DOWNES CEJ, Rehn J, Heatley SL, Yeung D, et al
    Identification of a novel GOLGA4-JAK2 fusion gene in B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2022;196:700-705.
    PubMed     Abstract available

  129. SCHWAB CJ, Murdy D, Butler E, Enshaei A, et al
    Genetic characterisation of childhood B-other-acute lymphoblastic leukaemia in UK patients by fluorescence in situ hybridisation and Multiplex Ligation-dependent Probe Amplification.
    Br J Haematol. 2022;196:753-763.
    PubMed     Abstract available

  130. TANDON S, Visser R, Astwood E, Payne J, et al
    Paediatric ambiguous lineage leukaemia with monocytic differentiation at diagnosis: case series and review of literature.
    Br J Haematol. 2022;196:e34-e39.

  131. KRIEG S, Seeger H, Hofmann P, Del Prete C, et al
    Baseline creatinine predicts acute kidney injury during intensive therapy in transplant-eligible patients with acute myeloid leukaemia.
    Br J Haematol. 2022;196:781-784.

  132. VOJDEMAN FJ, Helby J, Pedersen LB, Brieghel C, et al
    Chronic lymphocytic leukaemia clones are detectable decades before diagnosis.
    Br J Haematol. 2022;196:784-787.

  133. HUANG W, Sundquist K, Sundquist J, Ji J, et al
    Use of dipyridamole is associated with lower risk of lymphoid neoplasms: a propensity score-matched cohort study.
    Br J Haematol. 2022;196:690-699.
    PubMed     Abstract available

  134. RIBERA J, Granada I, Morgades M, Gonzalez T, et al
    Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols.
    Br J Haematol. 2022;196:670-675.
    PubMed     Abstract available

  135. BOOTH S, Curley HM, Varnai C, Arnold R, et al
    Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: disease control as an important factor relative to recent chemotherapy or anti-CD20 therapy.
    Br J Haematol. 2022;196:892-901.
    PubMed     Abstract available

  136. ALLAN JN, Shanafelt T, Wiestner A, Moreno C, et al
    Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.
    Br J Haematol. 2022;196:947-953.
    PubMed     Abstract available

  137. AHMED HMM, Nimmagadda SC, Al-Matary YS, Fiori M, et al
    Dexamethasone-mediated inhibition of Notch signalling blocks the interaction of leukaemia and mesenchymal stromal cells.
    Br J Haematol. 2022;196:995-1006.
    PubMed     Abstract available

  138. SHEN Z, Zhou M, Zhang J, Chen S, et al
    Microgranular variant of acute promyelocytic leukaemia with an unusual T/myeloid immunophenotype resembling that of mixed-phenotype acute leukaemia.
    Br J Haematol. 2022;196:801.

  139. ABDEL RAHMAN ZH, Parrondo RD, Heckman MG, Wieczorek M, et al
    Comparative study of therapy-related and de novo adult b-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2022;196:963-968.
    PubMed     Abstract available

  140. EYRE TA, Riches JC, Patten PEM, Walewska R, et al
    Richter transformation of chronic lymphocytic leukaemia: a British Society for Haematology Good Practice Paper.
    Br J Haematol. 2022;196:864-870.

    January 2022
  141. TOMOWIAK C, Leblond V, Laribi K, Baron M, et al
    Response to vaccination against SARS-CoV-2 in 168 patients with Waldenstrom macroglobulinemia: a French Innovative Leukemia Organization (FILO) study.
    Br J Haematol. 2022 Jan 14. doi: 10.1111/bjh.18055.

  142. NAVILLE AS, Lazaro E, Boutin J, Prot-Leurent C, et al
    Acquired glucose 6-phosphate dehydrogenase (G6PD) deficiency in a patient with Chronic Myelomonocytic Leukemia.
    Br J Haematol. 2022 Jan 6. doi: 10.1111/bjh.18037.

  143. SAULTIER P, Ninove L, Szepetowski S, Veneziano M, et al
    Monoclonal antibodies for the treatment of COVID-19 in a patient with high-risk acute leukaemia.
    Br J Haematol. 2022;196:e1-e3.

  144. MARCHESI F, Pimpinelli F, Sperandio E, Papa E, et al
    The 12-week kinetics of anti-SARS-CoV-2 antibodies in different haematological cancers after vaccination with BNT162b2.
    Br J Haematol. 2022;196:362-367.

  145. GASTINNE T, Le Bourgeois A, Coste-Burel M, Guillaume T, et al
    Safety and antibody response after one and/or two doses of BNT162b2 Anti-SARS-CoV-2 mRNA vaccine in patients treated by CAR T cells therapy.
    Br J Haematol. 2022;196:360-362.

  146. SEVIAR D, Nyunt K, Sayer C, Wright D, et al
    Romboutsia-induced bone marrow necrosis at presentation of acute myeloid leukaemia.
    Br J Haematol. 2022;196:262.

  147. YAO H, Huo L, Ping N, Liu H, et al
    Recurrent mutations in multiple components of the SWI/SNF complex in myelodysplastic syndromes and acute myeloid leukaemia.
    Br J Haematol. 2022;196:441-444.

  148. KIM DDH, Kim TS, Atenafu EG, Novitzky Basso I, et al
    BCR-ABL1 transcript doubling time as a predictor for treatment-free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase.
    Br J Haematol. 2022;196:136-145.
    PubMed     Abstract available

  149. LOKE J, Metzner M, Boucher R, Jackson A, et al
    Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapy.
    Br J Haematol. 2022;196:368-373.
    PubMed     Abstract available

  150. PODVIN B, Goursaud L, Roynard P, Nibourel O, et al
    Chronic myeloid leukaemia presenting with monocytosis.
    Br J Haematol. 2022;196:8.

  151. NAKAJIMA R, Matsuo T, Sumiyoshi R, Saito S, et al
    Extramedullary blast crisis in a chronic myeloid leukaemia patient after achieving a major molecular response with bosutinib.
    Br J Haematol. 2022;196:e9-e11.

  152. KAYSER S, Levis MJ
    Updates on targeted therapies for acute myeloid leukaemia.
    Br J Haematol. 2022;196:316-328.
    PubMed     Abstract available

  153. MIKHAILOVA E, Roumiantseva J, Illarionova O, Lagoyko S, et al
    Strong expansion of normal CD19-negative B-cell precursors after the use of blinatumomab in the first-line therapy of acute lymphoblastic leukaemia in children.
    Br J Haematol. 2022;196:e6-e9.

  154. SHANMUGANATHAN N, Branford S
    Multiplex technologies for the assessment of minimal residual disease and low-level mutation detection in leukaemia: mass spectrometry versus next-generation sequencing.
    Br J Haematol. 2022;196:19-30.
    PubMed     Abstract available

    December 2021
  155. FOX TA, Kirkwood AA, Enfield L, O'Reilly M, et al
    Low seropositivity and suboptimal neutralisation rates in patients fully vaccinated against COVID-19 with B-cell malignancies.
    Br J Haematol. 2021;195:706-709.

  156. KIM HS, Lee JW, Kang D, Yu H, et al
    Characteristics of RAS pathway mutations in juvenile myelomonocytic leukaemia: a single-institution study from Korea.
    Br J Haematol. 2021;195:748-756.
    PubMed     Abstract available

  157. MINGUELA A, Salido EJ, Soto-Ramirez MF, Olga MA, et al
    Low-affinity immunoglobulin gamma Fc region receptor III-B (FcgammaRIIIB, CD16B) deficiency in patients with blood and immune system disorders.
    Br J Haematol. 2021;195:743-747.
    PubMed     Abstract available

  158. SILLA L, Valim V, Pezzi A, da Silva M, et al
    Adoptive immunotherapy with double-bright (CD56(bright) /CD16(bright) ) expanded natural killer cells in patients with relapsed or refractory acute myeloid leukaemia: a proof-of-concept study.
    Br J Haematol. 2021;195:710-721.
    PubMed     Abstract available

  159. TANG FF, Lu SY, Zhao XS, Qin YZ, et al
    PML-RARA transcript levels at the end of induction therapy are associated with prognosis in non-high-risk acute promyelocytic leukaemia with all-trans retinoic acid plus arsenic in front-line therapy: long-term follow-up of a single-centre cohort stud
    Br J Haematol. 2021;195:722-730.
    PubMed     Abstract available

    November 2021
  160. FOX CP, Ahearne MJ, Pettengell R, Dearden C, et al
    Guidelines for the management of mature T- and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma): a British Society for Haematology Guideline.
    Br J Haematol. 2021 Nov 22. doi: 10.1111/bjh.17951.

  161. BENDA M, Mutschlechner B, Ulmer H, Grabher C, et al
    Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients.
    Br J Haematol. 2021;195:523-531.
    PubMed     Abstract available

  162. SHIMONI A, Robin M, Iacobelli S, Beelen D, et al
    Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT.
    Br J Haematol. 2021;195:417-428.
    PubMed     Abstract available

  163. HWANG J, Singh N, Braniecki M, Gok Yavuz B, et al
    Omacetaxine added to a standard acute myeloid leukaemia chemotherapy regimen reduces cellular FLIP levels, markedly increasing the incidence of eccrine hidradenitis.
    Br J Haematol. 2021;195:e138-e141.

  164. SMYTH L, Blunt DN, Cheung MC
    Statins in mature B-cell lymphomas and leukaemias.
    Br J Haematol. 2021;195:490-492.

  165. SOLANO DE LA ASUNCION C, Terol MJ, Saus A, Olea B, et al
    Cytomegalovirus-specific T-cell immunity and DNAemia in patients with chronic lymphocytic leukaemia undergoing treatment with ibrutinib.
    Br J Haematol. 2021;195:637-641.

  166. BEGNA KH, Kittur J, Yui J, Gangat N, et al
    De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases.
    Br J Haematol. 2021;195:413-416.
    PubMed     Abstract available

  167. ZHONG ZQ, Zhuang HF, Wu SL, Zhang H, et al
    Pseudo-Chediak-Higashi inclusions in relapsed acute lymphoblastic leukaemia.
    Br J Haematol. 2021;195:300.

  168. SKOU AS, Juul-Dam KL, Ommen HB, Hasle H, et al
    Peripheral blood molecular measurable residual disease is sufficient to identify patients with acute myeloid leukaemia with imminent clinical relapse.
    Br J Haematol. 2021;195:310-327.
    PubMed     Abstract available

    October 2021
  169. NOSAKA K, Kusumoto S, Nakano N, Choi I, et al
    Clinical significance of the immunoglobulin G heavy-chain repertoire in peripheral blood mononuclear cells of adult T-cell leukaemia-lymphoma patients receiving mogamulizumab.
    Br J Haematol. 2021 Oct 10. doi: 10.1111/bjh.17895.
    PubMed     Abstract available

  170. LIU M, Zhao X, Pan W, Qian Z, et al
    A novel HNRNPC-RARA fusion in acute promyelocytic leukaemia lacking PML-RARA rearrangement, sensitive to venetoclax-based therapy.
    Br J Haematol. 2021;195:e123-e128.

  171. BARTRAM J, Balasch-Carulla M, Bhojaraja S, Adams S, et al
    Blinatumomab for paediatric mixed phenotype acute leukaemia.
    Br J Haematol. 2021;195:289-292.

  172. EDWARDS K, Zaitseva K, Sayed U, Volpi EV, et al
    Expression patterns of CD180 in the lymph nodes of patients with chronic lymphocytic leukaemia.
    Br J Haematol. 2021;195:e131-e134.

  173. TESTI AM, Mohamed S, Diverio D, Piciocchi A, et al
    Outcome of relapsed/refractory acute promyelocytic leukaemia in children, adolescents and young adult patients - a 25-year Italian experience.
    Br J Haematol. 2021;195:278-283.

  174. BEZDEKOVA R, Jelinek T, Kralova R, Stork M, et al
    Necessity of flow cytometry assessment of circulating plasma cells and its connection with clinical characteristics of primary and secondary plasma cell leukaemia.
    Br J Haematol. 2021;195:95-107.
    PubMed     Abstract available

  175. GOULD C, Lickiss J, Kankanige Y, Yerneni S, et al
    Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic target.
    Br J Haematol. 2021;195:113-118.
    PubMed     Abstract available

  176. THASTRUP M, Marquart HV, Levinsen M, Modvig S, et al
    Flow cytometric analysis of cerebrospinal fluid improves detection of leukaemic blasts in infants with acute lymphoblastic leukaemia.
    Br J Haematol. 2021;195:119-122.
    PubMed     Abstract available

  177. O'CONNOR D, Loke J, Brown M, Stanworth SJ, et al
    Non-pharmacological supportive-care interventions in acute myeloid leukaemia: a review of randomised controlled trials.
    Br J Haematol. 2021;195:e97-e113.

  178. MAENG CV, Ostgard LSG, Christiansen CF, Liu KD, et al
    Changes in intensive care unit admission rates, organ support, and mortality in patients with acute myeloid leukaemia over a 12-year period: a Danish nationwide cohort study.
    Br J Haematol. 2021;195:137-140.

    September 2021
  179. COOK LBM
    Adult T-cell leukaemia/lymphoma and the trouble with TP53.
    Br J Haematol. 2021 Sep 9. doi: 10.1111/bjh.17830.

  180. CHATTERJEE G, Sriram H, Ghogale S, Deshpande N, et al
    Mimics and artefacts of measurable residual disease in a highly sensitive multicolour flow cytometry assay for B-lymphoblastic leukaemia/lymphoma: critical consideration for analysis of measurable residual disease.
    Br J Haematol. 2021 Sep 2. doi: 10.1111/bjh.17801.
    PubMed     Abstract available

  181. CHOWDHURY O, Bruguier H, Mallett G, Sousos N, et al
    Impaired antibody response to COVID-19 vaccination in patients with chronic myeloid neoplasms.
    Br J Haematol. 2021;194:1010-1015.

  182. HARRINGTON P, Doores KJ, Radia D, O'Reilly A, et al
    Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia.
    Br J Haematol. 2021;194:999-1006.
    PubMed     Abstract available

  183. A special issue on modern genomics in diagnostic haematology.
    Br J Haematol. 2021;194:801-802.

  184. KUIPER RP, Hoogeveen PG, Bladergroen R, van Dijk F, et al
    Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all.
    Br J Haematol. 2021;194:888-892.
    PubMed     Abstract available

  185. KHAN M, Roddy JT, Hernandez JR, Bursch K, et al
    Revisiting biochemistry: severe euglycemic ketoacidosis in the setting of IDH-inhibitor therapy for AML.
    Br J Haematol. 2021;194:1083-1085.

  186. RASCHE A, Mason EF, Strickland SA, Byrne M, et al
    Isocitrate dehydrogenase inhibitor-driven differentiation may resemble secondary graft failure in post-allogeneic haematopoietic cell transplantation relapsed acute myeloid leukaemia.
    Br J Haematol. 2021;194:927-931.

  187. ALCALDE-MELLADO P, Franco-Macias E, Morales-Camacho RM, Caballero-Velazquez T, et al
    Auer rod-like inclusions in cerebrospinal fluid in accelerated phase chronic lymphocytic leukaemia.
    Br J Haematol. 2021;194:946.

    August 2021
  188. SAKAMOTO Y, Ishida T, Masaki A, Murase T, et al
    Clinical significance of TP53 mutations in adult T-cell leukemia/lymphoma.
    Br J Haematol. 2021 Aug 17. doi: 10.1111/bjh.17749.
    PubMed     Abstract available

  189. FANG H, Wang W, El Hussein S, Morita K, et al
    B-cell lymphoma/leukaemia 11B (BCL11B) expression status helps distinguish early T-cell precursor acute lymphoblastic leukaemia/lymphoma (ETP-ALL/LBL) from other subtypes of T-cell ALL/LBL.
    Br J Haematol. 2021 Aug 16. doi: 10.1111/bjh.17681.
    PubMed     Abstract available

  190. HENRY A, Bracquemart C, Naguib D, Chantepie S, et al
    Does eventually NPM1 mutation in blast phase chronic myeloid leukemia (BP-CML) exist? That is the question.
    Br J Haematol. 2021 Aug 15. doi: 10.1111/bjh.17761.

  191. PATEL PA, Lapp SA, Grubbs G, Edara VV, et al
    Immune responses and therapeutic challenges in paediatric patients with new-onset acute myeloid leukaemia and concomitant COVID-19.
    Br J Haematol. 2021;194:549-553.

  192. LUCCHINI G, Furness C, Lawson S, Gibson B, et al
    COVID-19 infection in paediatric recipients of allogeneic stem cell transplantation: the UK experience.
    Br J Haematol. 2021;194:e74-e77.

  193. YEOH AEJ, Oh BL, Ariffin H
    Doing less, accomplishing more for childhood acute lymphoblastic leukaemia (ALL).
    Br J Haematol. 2021;194:661-662.

  194. NOURA M, Morita K, Kiyose H, Okuno Y, et al
    Albendazole induces the terminal differentiation of acute myeloid leukaemia cells to monocytes by stimulating the Kruppel-like factor 4-dihydropyrimidinase-like 2A (KLF4-DPYSL2A) axis.
    Br J Haematol. 2021;194:598-603.
    PubMed     Abstract available

  195. RAMDENY PS, Mullanfroze K, de Lorenzo P, Grazia Valsecchi M, et al
    Infant T-cell acute lymphoblastic leukaemia with t(6;7) (TCRB-MYB) translocation.
    Br J Haematol. 2021;194:613-616.
    PubMed     Abstract available

  196. ROMZOVA M, Smitalova D, Hynst J, Tom N, et al
    Hierarchical distribution of somatic variants in newly diagnosed chronic myeloid leukaemia at diagnosis and early follow-up.
    Br J Haematol. 2021;194:604-612.
    PubMed     Abstract available

  197. MASLAH N, Diawara Y, Sebert M, Giraudier S, et al
    In vitro assessment of the sensitivity to APR-246 + azacitidine combination predicts response to this combination in myelodysplastic/acute myeloid leukaemia patients.
    Br J Haematol. 2021;194:e77-e79.

  198. JENSEN KS, Oskarsson T, Lahteenmaki PM, Flaegstad T, et al
    Detection mode of childhood acute lymphoblastic leukaemia relapse and its effect on survival: a Nordic population-based cohort study.
    Br J Haematol. 2021;194:734-744.
    PubMed     Abstract available

  199. CORNEAU A, Parizot C, Cherai M, Todesco E, et al
    Mass Cytometry: a robust platform for the comprehensive immunomonitoring of CAR-T-cell therapies.
    Br J Haematol. 2021;194:788-792.

  200. ALLSUP D, Howard D, Emmerson J, Hockaday A, et al
    COSMIC, chemotherapy plus ofatumumab at standard or mega-dose in chronic lymphocytic leukaemia, a phase II randomised study.
    Br J Haematol. 2021;194:646-650.

  201. LOBO-OLMEDO A, Roldan Galiacho V, Arzuaga-Mendez J, Ancin I, et al
    Acute megakaryoblastic leukaemia with erythrophagocytosis.
    Br J Haematol. 2021;194:658.

    July 2021
  202. BRANVALL E, Ekberg S, Eloranta S, Wasterlid T, et al
    Statin use and survival in 16 098 patients with non-Hodgkin lymphoma or chronic lymphocytic leukaemia treated in the rituximab era.
    Br J Haematol. 2021 Jul 31. doi: 10.1111/bjh.17733.
    PubMed     Abstract available

  203. MOIA R, Favini C, Ferri V, Forestieri G, et al
    Multiregional sequencing and circulating tumour DNA analysis provide complementary approaches for comprehensive disease profiling of small lymphocytic lymphoma.
    Br J Haematol. 2021 Jul 22. doi: 10.1111/bjh.17718.
    PubMed     Abstract available

    What is the right dosage of dasatinib for treating chronic myeloid leukaemia?
    Br J Haematol. 2021;194:234.

  205. ROUSSELOT P, Mollica L, Guilhot J, Guerci A, et al
    Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients.
    Br J Haematol. 2021;194:393-402.
    PubMed     Abstract available

  206. NAKAMURA M, Arai Y, Hirabayashi S, Kondo T, et al
    Residual disease is a strong prognostic marker in patients with acute lymphoblastic leukaemia with chemotherapy-refractory or relapsed disease prior to allogeneic stem cell transplantation.
    Br J Haematol. 2021;194:403-413.
    PubMed     Abstract available

  207. COMONT T, Meunier M, Cherait A, Santana C, et al
    Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective real-life study.
    Br J Haematol. 2021;194:336-343.
    PubMed     Abstract available

  208. WIERNIK PH, Sun Z, Cripe LD, Rowe JM, et al
    Prognostic effect of gender on outcome of treatment for adults with acute myeloid leukaemia.
    Br J Haematol. 2021;194:309-318.
    PubMed     Abstract available

  209. ROEKER LE, Thompson MC, Mato AR
    Searching for a home: phosphoinositide 3-kinase inhibitors for chronic lymphocytic leukaemia in modern clinical practice.
    Br J Haematol. 2021;194:9-10.

  210. MULRONEY CM, Abid MB, Bashey A, Chemaly RF, et al
    Incidence and impact of community respiratory viral infections in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical stem cell transplantation.
    Br J Haematol. 2021;194:145-157.
    PubMed     Abstract available

  211. EYRE TA, Preston G, Kagdi H, Islam A, et al
    A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO-idel).
    Br J Haematol. 2021;194:69-77.
    PubMed     Abstract available

  212. SASAKI K, Tsujimoto S, Miyake M, Uchiyama Y, et al
    Droplet digital polymerase chain reaction assay for the detection of the minor clone of KIT D816V in paediatric acute myeloid leukaemia especially showing RUNX1-RUNX1T1 transcripts.
    Br J Haematol. 2021;194:414-422.
    PubMed     Abstract available

  213. SCOTT S, Cartwright A, Francis S, Whitby L, et al
    Assessment of droplet digital polymerase chain reaction for measuring BCR-ABL1 in chronic myeloid leukaemia in an international interlaboratory study.
    Br J Haematol. 2021;194:53-60.
    PubMed     Abstract available

  214. RADICH J
    Building a better mousetrap for accurate and sensitive polymerase chain reaction.
    Br J Haematol. 2021;194:11-13.

  215. SASSEN SDT, Mathot RAA, Pieters R, de Haas V, et al
    Evaluation of the pharmacokinetics of prednisolone in paediatric patients with acute lymphoblastic leukaemia treated according to Dutch Childhood Oncology Group protocols and its relation to treatment response.
    Br J Haematol. 2021;194:423-432.
    PubMed     Abstract available

  216. KOUKOULIAS K, Papadopoulou A, Kouimtzidis A, Papayanni PG, et al
    Non-transplantable cord blood units as a source for adoptive immunotherapy of leukaemia and a paradigm of circular economy in medicine.
    Br J Haematol. 2021;194:158-167.
    PubMed     Abstract available

  217. BODOR C, Kotmayer L, Laszlo T, Takacs F, et al
    Screening and monitoring of the BTK(C481S) mutation in a real-world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy.
    Br J Haematol. 2021;194:355-364.
    PubMed     Abstract available

  218. MICHALOWSKI MB, Cecconello DK, Lins MM, Carvalho MDPSS, et al
    Influence of different asparaginase formulations in the prognosis of children with acute lymphocytic leukaemia in Brazil: a multicentre, retrospective controlled study.
    Br J Haematol. 2021;194:168-173.
    PubMed     Abstract available

  219. ZHAO Y, McCracken J, Rehder C, Wang E, et al
    Biclonal evolution of chronic lymphocytic leukaemia.
    Br J Haematol. 2021;194:e64-e66.

  220. CHERNG HJ, Jammal N, Paul S, Wang X, et al
    Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia.
    Br J Haematol. 2021;194:61-68.
    PubMed     Abstract available

  221. DENNIS M, Burnett A, Hills R, Thomas I, et al
    A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial.
    Br J Haematol. 2021;194:298-308.
    PubMed     Abstract available

  222. POCOCK R, Farah N, Richardson SE, Mansour MR, et al
    Current and emerging therapeutic approaches for T-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2021;194:28-43.
    PubMed     Abstract available

  223. ASSANTO GM, Riemma C, Malaspina F, Perrone S, et al
    The current role of interferon in hairy cell leukaemia: clinical and molecular aspects.
    Br J Haematol. 2021;194:78-82.
    PubMed     Abstract available

  224. POPOV A, Fominikh V, Mikhailova E, Shelikhova L, et al
    Blinatumomab following haematopoietic stem cell transplantation - a novel approach for the treatment of acute lymphoblastic leukaemia in infants.
    Br J Haematol. 2021;194:174-178.
    PubMed     Abstract available

  225. KOLLA BC, Halim NAA, Cao Q, Sachs Z, et al
    High risk of relapse with intermediate dose cytarabine for consolidation in young favourable-risk acute myeloid leukaemia patients following induction with 7+3: a retrospective multicentre analysis and critical review of the literature.
    Br J Haematol. 2021;194:140-144.
    PubMed     Abstract available

  226. HSU H, Roncolato F, Lee SH
    Lysosomal acid lipase deficiency diagnosed in a patient presenting with acute myeloid leukaemia.
    Br J Haematol. 2021;194:228.

  227. SHACKLETON L, McCarthy J, Mykytiv V
    Extramedullary pericardial haematopoiesis as a presenting feature of chronic myeloid leukaemia.
    Br J Haematol. 2021;194:7.

    June 2021
  228. OSTERGAARD J, Jonart LM, Ebadi M, Koppenhafer SL, et al
    Preclinical efficacy of prexasertib in acute lymphoblastic leukemia.
    Br J Haematol. 2021 Jun 7. doi: 10.1111/bjh.17610.

  229. KARANTANOS T, Gondek LP, Varadhan R, Moliterno AR, et al
    Gender-related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
    Br J Haematol. 2021;193:1142-1150.
    PubMed     Abstract available

  230. XU R, Huang X, Li C, Deng C, et al
    Bone marrow mesenchymal stromal cells in chronic myelomonocytic leukaemia: overactivated WNT/beta-catenin signalling by parallel RNA sequencing and dysfunctional phenotypes.
    Br J Haematol. 2021;193:928-940.
    PubMed     Abstract available

  231. MOSKORZ W, Cosmovici C, Jager PS, Cadeddu RP, et al
    Myelodysplastic syndrome patients display alterations in their immune status reflected by increased PD-L1-expressing stem cells and highly dynamic exhausted T-cell frequencies.
    Br J Haematol. 2021;193:941-945.
    PubMed     Abstract available

  232. CAO H, Neerincx A, de Bono B, Lakner U, et al
    Sialic acid-binding immunoglobulin-like lectin (Sigelac)-15 is a rapidly internalised cell-surface antigen expressed by acute myeloid leukaemia cells.
    Br J Haematol. 2021;193:946-950.
    PubMed     Abstract available

  233. DHOLARIA B, Savani BN, Huang XJ, Nagler A, et al
    The evolving role of allogeneic haematopoietic cell transplantation in the era of chimaeric antigen receptor T-cell therapy.
    Br J Haematol. 2021;193:1060-1075.
    PubMed     Abstract available

  234. NISHIMURA A, Naruto T, Miyamoto S, Grigg A, et al
    Genomics analysis of leukaemia predisposition in X-linked agammaglobulinaemia.
    Br J Haematol. 2021;193:1277-1281.

  235. VAN DE GEER A, Zandstra J, Tanck MWT, Nur E, et al
    Biomarkers to predict infection and infection-related complications during chemotherapy-induced neutropenia in acute myeloid leukaemia: a pilot study.
    Br J Haematol. 2021;193:1008-1012.

  236. SHAH MV, Saliba RM, Varma A, Ciurea SO, et al
    Allogeneic stem cell transplant for patients with myeloproliferative neoplasms in blast phase: improving outcomes in the recent era.
    Br J Haematol. 2021;193:1004-1008.

  237. FLYGT H, Sandin F, Dahlen T, Dremaine A, et al
    Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry.
    Br J Haematol. 2021;193:915-921.
    PubMed     Abstract available

  238. WANG H, Zhou Y, Huang X, Zhang Y, et al
    Minimal residual disease level determined by flow cytometry provides reliable risk stratification in adults with T-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2021;193:1096-1104.
    PubMed     Abstract available

  239. CREUZET E, Nourrisson C, Chaleteix C, Poirier P, et al
    Cerebral aspergillosis in a patient on ibrutinib therapy.
    Br J Haematol. 2021;193:1025.

  240. DANDER E, Fallati A, Gulic T, Pagni F, et al
    Monocyte-macrophage polarization and recruitment pathways in the tumour microenvironment of B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2021;193:1157-1171.
    PubMed     Abstract available

  241. TSAUR G, Popov A, Riger T, Kustanovich A, et al
    Prognostic value of minimal residual disease measured by fusion-gene transcript in infants with KMT2A-rearranged acute lymphoblastic leukaemia treated according to the MLL-Baby protocol.
    Br J Haematol. 2021;193:1151-1156.
    PubMed     Abstract available

  242. BRIVIO E, Chantrain CF, Gruber TA, Thano A, et al
    Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series.
    Br J Haematol. 2021;193:1172-1177.
    PubMed     Abstract available

  243. BRAS AE, Osmani Z, de Haas V, Jongen-Lavrencic M, et al
    Standardised immunophenotypic analysis of myeloperoxidase in acute leukaemia.
    Br J Haematol. 2021;193:922-927.
    PubMed     Abstract available

    May 2021
  244. CHANDER G, Nikolousis E, Kanellopoulos A
    Human papilloma virus (HPV)-associated lesions in a post-bone marrow transplant patient responding to HPV vaccination.
    Br J Haematol. 2021 May 2. doi: 10.1111/bjh.17514.

  245. ROSS DM
    How much imatinib is enough?
    Br J Haematol. 2021;193:699-700.

  246. KIM DDH, Novitzky-Basso I, Kim TS, Atenafu EG, et al
    Optimal duration of imatinib treatment/deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial.
    Br J Haematol. 2021;193:779-791.
    PubMed     Abstract available

  247. KHARFAN-DABAJA MA, Labopin M, Brissot E, Kroger N, et al
    Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia.
    Br J Haematol. 2021;193:592-601.
    PubMed     Abstract available

  248. AOKI K, Kurashige M, Ichii M, Higaki K, et al
    Identification of CXCL12-abundant reticular cells in human adult bone marrow.
    Br J Haematol. 2021;193:659-668.
    PubMed     Abstract available

  249. MIKHAILOVA E, Semchenkova A, Illarionova O, Kashpor S, et al
    Relative expansion of CD19-negative very-early normal B-cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR-T cell therapy: implications for flow cytometric detection of minimal residual disease.
    Br J Haematol. 2021;193:602-612.
    PubMed     Abstract available

  250. SEMBILL S, Gohring G, Schirmer E, Lutterloh F, et al
    Paediatric chronic myeloid leukaemia presenting in de novo or secondary blast phase - a comparison of clinical and genetic characteristics.
    Br J Haematol. 2021;193:613-618.
    PubMed     Abstract available

  251. DE MIGUEL SANCHEZ C, Robles de Castro D, Pison Herrero C, Perez Persona E, et al
    Primary plasma cell leukaemia presenting with flower-shaped nuclei.
    Br J Haematol. 2021;193:689.

  252. CHEN D, Chen W
    Salmon-coloured granules in residual acute myeloid leukaemia with t(8;21)(q22;q22.1); RUNX1-RUNX1T1.
    Br J Haematol. 2021;193:691.

  253. NOY-LOTAN S, Krasnov T, Dgany O, Jeison M, et al
    Incorporation of somatic panels for the detection of haematopoietic transformation in children and young adults with leukaemia predisposition syndromes and with acquired cytopenias.
    Br J Haematol. 2021;193:570-580.
    PubMed     Abstract available

  254. HJORT JAKOBSEN L, Stidsholt Roug A, Kiesbye Ovlisen A, Werenberg Marcher C, et al
    Temporal changes in survival among adult patients with acute myeloid leukaemia in the period 2000-2016: a Danish population-based study.
    Br J Haematol. 2021;193:482-487.
    PubMed     Abstract available

  255. SMOLEJ L
    Skipping a step: what happened to the design of randomized clinical trials in chronic lymphocytic leukaemia?
    Br J Haematol. 2021;193:723-726.
    PubMed     Abstract available

    April 2021
  256. DO C, Best OG, Thurgood L, Hotinski A, et al
    Insight into del17p low-frequency subclones in chronic lymphocytic leukaemia (CLL): data from the Australasian Leukaemia and Lymphoma Group (ALLG)/CLL Australian Research Consortium (CLLARC) CLL5 trial.
    Br J Haematol. 2021 Apr 13. doi: 10.1111/bjh.17394.
    PubMed     Abstract available

  257. ZHENG J, Wu S, Hu Y, Gao L, et al
    Management of ETV6-ABL1-positive childhood acute lymphoblastic leukaemia: report of two cases, a literature review and a call for action.
    Br J Haematol. 2021;193:197-200.

  258. GANESAN P, Jain H, Bagal B, Subramanian PG, et al
    Outcomes in adolescent and young adult acute lymphoblastic leukaemia: a report from the Indian Acute Leukaemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC).
    Br J Haematol. 2021;193:e1-e4.

  259. FITTER S, Bradey AL, Kok CH, Noll JE, et al
    CKLF and IL1B transcript levels at diagnosis are predictive of relapse in children with pre-B-cell acute lymphoblastic leukaemia.
    Br J Haematol. 2021;193:171-175.
    PubMed     Abstract available

  260. TROUSSARD X, Grever MR
    The revised guidelines for the diagnosis and management of hairy cell leukaemia and the hairy cell leukaemia variant.
    Br J Haematol. 2021;193:11-14.

  261. GAILLLARD B, Cornillet-Lefebvre P, Le QH, Maloum K, et al
    Clinical and biological features of B-cell neoplasms with CDK6 translocations: an association with a subgroup of splenic marginal zone lymphomas displaying frequent CD5 expression, prolymphocytic cells, and TP53 abnormalities.
    Br J Haematol. 2021;193:72-82.
    PubMed     Abstract available

  262. SMOLEJ L, Turcsanyi P, Kubova Z, Zuchnicka J, et al
    External validation of International Prognostic Score for asymptomatic early stage chronic lymphocytic leukaemia and proposal of an alternative score.
    Br J Haematol. 2021;193:133-137.
    PubMed     Abstract available

  263. DANILOV AV, Persky DO
    Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.
    Br J Haematol. 2021;193:15-25.
    PubMed     Abstract available

  264. RASTOGI N, Baker S, Man S, Uger RA, et al
    Use of an anti-CD200-blocking antibody improves immune responses to AML in vitro and in vivo.
    Br J Haematol. 2021;193:155-159.
    PubMed     Abstract available

  265. GURNARI C, Breccia M, Di Giuliano F, Scalzulli E, et al
    Early intracranial haemorrhages in acute promyelocytic leukaemia: analysis of neuroradiological and clinico-biological parameters.
    Br J Haematol. 2021;193:129-132.
    PubMed     Abstract available

  266. STILGENBAUER S, Bosch F, Ilhan O, Kisro J, et al
    Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study.
    Br J Haematol. 2021;193:325-338.
    PubMed     Abstract available

  267. DA CUNHA-BANG C, Rostgaard K, Andersen MA, Rotbain EC, et al
    Risk of new malignancies among patients with CLL treated with chemotherapy: results of a Danish population-based study.
    Br J Haematol. 2021;193:339-345.
    PubMed     Abstract available

  268. SOVERINI S, Martelli M, Bavaro L, De Benedittis C, et al
    Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
    Br J Haematol. 2021;193:271-279.
    PubMed     Abstract available

  269. CLAUDIANI S, Apperley JF, Szydlo R, Khan A, et al
    TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia.
    Br J Haematol. 2021;193:346-355.
    PubMed     Abstract available

  270. DILLON R, Potter N, Freeman S, Russell N, et al
    How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML).
    Br J Haematol. 2021;193:231-244.
    PubMed     Abstract available

    March 2021
    Flow cytometry reveals the nuances of clonal haematopoiesis.
    Br J Haematol. 2021;192:949-950.

  272. BECKER MW, Angelucci E
    A large co-operative biological and clinical study to better understand and improve treatment of the rare t(8;16)(p11;p13) acute myeloid leukaemia.
    Br J Haematol. 2021;192:800-802.

  273. LOGHAVI S, DiNardo CD, Furudate K, Takahashi K, et al
    Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia.
    Br J Haematol. 2021;192:1054-1063.
    PubMed     Abstract available

  274. SCHLIEMANN C, Kessler T, Berdel AF, Hemmerle T, et al
    Phase I study of F16IL2 antibody-cytokine fusion with very low-dose araC in acute myeloid leukaemia relapse after allogeneic stem cell transplantation.
    Br J Haematol. 2021;192:e148-e151.

  275. FERRARI A, Ghelli Luserna Di Rora A, Domizio C, Papayannidis C, et al
    Rearrangements of ATP5L-KMT2A in acute lymphoblastic leukaemia.
    Br J Haematol. 2021;192:e139-e144.

  276. RIGOLIN GM, Saccenti E, Melandri A, Cavallari M, et al
    In chronic lymphocytic leukaemia, SLAMF1 deregulation is associated with genomic complexity and independently predicts a worse outcome.
    Br J Haematol. 2021;192:1068-1072.
    PubMed     Abstract available

  277. TIONG IS, Dillon R, Ivey A, Teh TC, et al
    Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia.
    Br J Haematol. 2021;192:1026-1030.
    PubMed     Abstract available

  278. QU S, Li B, Qin T, Xu Z, et al
    Molecular and clinical features of myeloid neoplasms with somatic DDX41 mutations.
    Br J Haematol. 2021;192:1006-1010.
    PubMed     Abstract available

  279. LUNDIN-STROM KB, Biloglav A, Lazarevic V, Behrendtz M, et al
    Parental origin of monosomy 7 in acute leukaemia.
    Br J Haematol. 2021;192:e132-e135.

  280. KAYSER S, Hills RK, Langova R, Kramer M, et al
    Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study.
    Br J Haematol. 2021;192:832-842.
    PubMed     Abstract available

    February 2021
  281. SMOLEJ L, Brychtova Y, Cmunt E, Doubek M, et al
    Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL St
    Br J Haematol. 2021 Feb 22. doi: 10.1111/bjh.17373.
    PubMed     Abstract available

  282. WOUTERS Y, Nevejan L, Louwagie A, Devos H, et al
    Efficacy of ruxolitinib in B-lymphoblastic leukaemia with the PCM1-JAK2 fusion gene.
    Br J Haematol. 2021;192:e112-e115.

  283. WANG J
    Leukaemia blues - an unusual presentation of leukaemia cutis.
    Br J Haematol. 2021;192:676.

  284. GORDON MJ, Huang J, Chan RJ, Bhargava P, et al
    Medical comorbidities in patients with chronic lymphocytic leukaemia treated with idelalisib: analysis of two large randomised clinical trials.
    Br J Haematol. 2021;192:720-728.
    PubMed     Abstract available

  285. EGHOLM GJ, Andersen MA, Andersen CL, Frederiksen H, et al
    Abnormal eosinophil count at CLL diagnosis correlates with shorter treatment free survival.
    Br J Haematol. 2021;192:e81-e84.

  286. HOTINSKI AK, Best OG, Thurgood LA, Lower KM, et al
    A biclonal case of chronic lymphocytic leukaemia with discordant mutational status of the immunoglobulin heavy chain variable region and bimodal CD49d expression.
    Br J Haematol. 2021;192:e77-e81.

  287. ALI AM, Cooper J, Walker A, Jones D, et al
    Adult-onset acute myeloid leukaemia in a patient with germline mutation of CBL.
    Br J Haematol. 2021;192:665-667.

  288. BRAUNSTEIN Z, Mishra A, Staub A, Freud AG, et al
    Clinical outcomes in T-cell large granular lymphocytic leukaemia: prognostic factors and treatment response.
    Br J Haematol. 2021;192:484-493.
    PubMed     Abstract available

  289. FLOETH M, Elges S, Gerss J, Schwoppe C, et al
    Low-density lipoprotein receptor (LDLR) is an independent adverse prognostic factor in acute myeloid leukaemia.
    Br J Haematol. 2021;192:494-503.
    PubMed     Abstract available

  290. MORENO BERGGREN D, Kjellander M, Backlund E, Engvall M, et al
    Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study.
    Br J Haematol. 2021;192:474-483.
    PubMed     Abstract available

  291. DIAMANTI P, Ede BC, Dace PE, Barendt WJ, et al
    Investigating the response of paediatric leukaemia-propagating cells to BCL-2 inhibitors.
    Br J Haematol. 2021;192:577-588.
    PubMed     Abstract available

    January 2021
  292. BRECCIA M
    Autologous stem cell transplantation finds a place in acute promyelocytic leukaemia.
    Br J Haematol. 2021;192:237-238.

  293. ROSS DM, Hughes TP
    Counterpoint: There is a best duration of deep molecular response for treatment-free remission, but it is patient-specific, and that is the challenge.
    Br J Haematol. 2021;192:24-27.
    PubMed     Abstract available

  294. KARAGIANNIS P, Alsdorf W, Tallarek AC, Blohm ME, et al
    Treatment of refractory acute myeloid leukaemia during pregnancy with venetoclax, high-dose cytarabine and mitoxantrone.
    Br J Haematol. 2021;192:e60-e63.

  295. FOUZIA NA, Sharma V, Ganesan S, Palani HK, et al
    Management of relapse in acute promyelocytic leukaemia treated with up-front arsenic trioxide-based regimens.
    Br J Haematol. 2021;192:292-299.
    PubMed     Abstract available

  296. JIN W, Chen L, Liu Y, Chen Q, et al
    A novel KMT2A-USO1 fusion gene-induced de novo secondary acute myeloid leukaemia in a patient initially diagnosed with acute promyelocytic leukaemia.
    Br J Haematol. 2021;192:e32-e36.

  297. OTTAVIANO G, Baird S, Bonney D, Connor P, et al
    The role of immunotherapy in relapse/refractory precursor-B acute lymphoblastic leukaemia: real-life UK/Ireland experience in children and young adults.
    Br J Haematol. 2021;192:e42-e44.

  298. CAVALLINI C, Galasso M, Pozza ED, Chignola R, et al
    Effects of CD20 antibodies and kinase inhibitors on B-cell receptor signalling and survival of chronic lymphocytic leukaemia cells.
    Br J Haematol. 2021;192:333-342.
    PubMed     Abstract available

  299. GALE RP, Saglio G
    Point: Is there a best duration of deep molecular response to achieve therapy-free remission in chronic myeloid leukaemia?
    Br J Haematol. 2021;192:22-23.

  300. MATSUO H, Wakita T, Hiramatsu H, Ohmori K, et al
    Blast cells in acute megakaryoblastic leukaemia with Down syndrome are characterized by low CLEC12A expression.
    Br J Haematol. 2021;192:e7-e11.

  301. MASON CC, Fiol CR, Baker MJ, Nadal-Melsio E, et al
    Identification of genetic targets in acute myeloid leukaemia for designing targeted therapy.
    Br J Haematol. 2021;192:137-145.
    PubMed     Abstract available

  302. FRISANCO OLIVEIRA A, Tansini A, Toledo TR, Balceiro R, et al
    Immunophenotypic characteristics of juvenile myelomonocytic leukaemia and their relation with the molecular subgroups of the disease.
    Br J Haematol. 2021;192:129-136.
    PubMed     Abstract available

  303. RADICH J
    Molecular testing of chronic myeloid leukaemia in low resource areas.
    Br J Haematol. 2021;192:28-32.
    PubMed     Abstract available

  304. DUAN W, Liu X, Jia J, Wang J, et al
    The loss or absence of minimal residual disease of <0.1% at any time after two cycles of consolidation chemotherapy in CBFB-MYH11-positive acute myeloid leukaemia indicates poor prognosis.
    Br J Haematol. 2021;192:265-271.
    PubMed     Abstract available

  305. MILOJKOVIC D, Cross NCP, Ali S, Byrne J, et al
    Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study.
    Br J Haematol. 2021;192:62-74.
    PubMed     Abstract available

    December 2020
  306. NAKAHATA S, Morishita K
    Commentary on: clinical significance of CD28 gene-related activating alterations in adult T-cell leukaemia/lymphoma.
    Br J Haematol. 2020 Dec 14. doi: 10.1111/bjh.17214.

    November 2020
  307. ZHANG X, Suo S, Wang J, Jin J, et al
    IDH1(R132S) -mutated acute lymphoblastic leukaemia resembles Burkitt lymphoma/leukaemia via activating MYC.
    Br J Haematol. 2020 Nov 21. doi: 10.1111/bjh.17199.

  308. SAKAMOTO Y, Ishida T, Masaki A, Takeshita M, et al
    Clinical significance of CD28 gene-related activating alterations in adult T-cell leukaemia/lymphoma.
    Br J Haematol. 2020 Nov 18. doi: 10.1111/bjh.17211.
    PubMed     Abstract available

    October 2020
  309. HERISHANU Y, Levi S, Kamdjou T, Bornstein Y, et al
    Obinutuzumab in the treatment of autoimmune haemolytic anaemia and immune thrombocytopenia in patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma.
    Br J Haematol. 2020 Oct 23. doi: 10.1111/bjh.17105.

    April 2020
  310. AOKI T, Takahashi H, Tanaka S, Shiba N, et al
    Predisposition to prolonged neutropenia after chemotherapy for paediatric acute myeloid leukaemia is associated with better prognosis in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study.
    Br J Haematol. 2020 Apr 26. doi: 10.1111/bjh.16656.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.